1Cuppone F,Bria E,Giannarelli D,et al.Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer:meta-analysis of randomized trials[J].BMC Cancer,2010,10 (9):675.
2Amato RJ,Hernandez-McClain J,Henary H.Bone-targeted therapy:phase Ⅱ study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer[J].Am J Clin Oncol,2008,31 (6):532-538.
3Petrioli R,Pascucci A,Conca R,et al.Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer:a randomised phase Ⅱstudy[J].Br J Cancer.2011,104(4):613-619.
4Couper JW,Love AW,Duchesne GM,et al.Predictors of psychosocial distress 12 months after diagnosis with early and advanced prostate cancer[J].Med J Aust.2010,193(5Suppl):S58-61.
5Spence MM,Hui RL,Chan J,et al.Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid[J].Ann Pharmacother.2010,44(9):1384-1388.
